A nationwide IV saline recall is underway after B. Braun Medical found rust and other foreign particles floating inside bags of the fluid it ships to hospitals.
The company is voluntarily recalling three lots of 0.9% Sodium Chloride Injection USP, the 100 mL size supplied in a 150 mL PAB container. The affected lot numbers are J6B435, J6B444, and J6B457, and all three went out to hospitals and healthcare facilities across the country between late February and early August. The Food and Drug Administration lists the particles found in the fluid as iron oxide, which is rust, along with cellulose, polystyrene, and other inorganic matter.
Saline is about as basic as hospital supplies get. It is salt water mixed to match the concentration of fluid already in the body, and it is the thing hanging on the pole when someone is dehydrated, in surgery, in labor, getting chemotherapy, or receiving almost any drug that has to be diluted before it goes into a vein. That is what makes this IV saline recall different from a food recall. Nothing filters it. Whatever is in the bag goes straight into the bloodstream.
There is a wrinkle in this one that a lot of the coverage still has wrong. When B. Braun first announced the recall, the company identified the particles as zinc oxide. On August 28, it corrected that to iron oxide, and the FDA notice now carries the correction at the top of the page. Plenty of articles published around the original announcement still name zinc oxide, so if you see that version somewhere, it is the outdated one.
B. Braun has not publicly explained how rust got into a sterile injectable product, whether it has identified the root cause, or how the first analysis named the wrong compound. The FDA also has not yet assigned the recall a classification, which is the ranking the agency gives every recall based on how serious the hazard is. That designation usually shows up in the agency’s weekly enforcement report after an announcement.
A second, separate recall is running at the same time and is getting folded into the same headlines. Baxter International is recalling two lots of 0.9% Sodium Chloride Injection USP in the 500 mL VIAFLEX plastic container because of possible fiberglass in the solution. Both lots expire October 31, 2027, and they were shipped to healthcare providers and distributors between July 31 and August 3. That recall went to a specific set of states rather than nationwide.
As for what the particles can actually do, Baxter’s own recall notice is blunt about it. The company warns that fiberglass entering the bloodstream can cause blockages and clotting in blood vessels and cut off blood flow to vital organs, and that severe cases could result in pulmonary embolism, which is a blockage in the arteries of the lungs, along with permanent organ damage or death. The notice also lists vein irritation, inflammatory reactions, worsening of infections a patient already has, and allergic reactions.
FDA guidance on particles in injectable products describes a similar range of outcomes, including infection, blockages in veins and arteries, microscopic blockages and abscesses inside organs, and inflammation where the needle went in. The guidance notes that particles delivered into a vein generally cause more trouble than the same particles injected under the skin or into muscle, and that children and older adults face higher risk than the general population.
None of that has happened yet, at least not that anyone has reported. Neither B. Braun nor Baxter nor the FDA has documented a single injury tied to any of the recalled products. Baxter said as of August 25 it had received no adverse event reports.
The practical part matters here because this is a hospital-level IV saline recall, not a consumer one. There is no bag in anyone’s medicine cabinet to check. Hospitals and healthcare facilities are the ones responsible for matching the lot numbers against their inventory, pulling the affected product off the shelf, and stopping its use. If you or someone in your family got an IV recently, that alone does not mean the saline came from a recalled lot. Millions of these bags are used every week, and only a handful of lots are involved.
If you are still concerned, the question to bring to your doctor or the facility is whether any of the listed lot numbers were in their supply during the window the product was distributed. Patients and clinicians can also report a suspected problem to the FDA through its adverse event reporting program.
What remains open is whether either recall grows. Recalls of injectable products sometimes expand once a manufacturer finishes its investigation, and the B. Braun action currently covers three lots of a single product size out of everything the company makes.
